[Translation] A randomized, open-label, two-sequence, two-period, crossover bioequivalence study of vonoprazan fumarate tablets in healthy subjects after single oral administration on an empty stomach or after a meal
主要目的:考察中国健康受试者在空腹/餐后条件下单剂量口服江苏利泰尔药业有限
公司(持有人:苏州第壹制药有限公司)生产的富马酸伏诺拉生片与 Takeda
Pharmaceutical Company Limited, Hikari Plant 生产的(持证商:Takeda Pharmaceutical
Company Limited)富马酸伏诺拉生片后的体内药代动力学特征,评价两制剂的生物
等效性;
次要目的:研究单剂量口服富马酸伏诺拉生片(规格:20mg)在中国健康受试者中
的安全性。
[Translation] Primary objective: To investigate the in vivo pharmacokinetic characteristics of vonoprazan fumarate tablets produced by Jiangsu Litaier Pharmaceutical Co., Ltd. (Owner: Suzhou No. 1 Pharmaceutical Co., Ltd.) and vonoprazan fumarate tablets produced by Takeda Pharmaceutical Company Limited, Hikari Plant (Certificate Holder: Takeda Pharmaceutical Company Limited) in healthy Chinese subjects after single oral administration under fasting/postprandial conditions, and to evaluate the bioequivalence of the two preparations; Secondary objective: To study the safety of single oral dose vonoprazan fumarate tablets (specification: 20 mg) in healthy Chinese subjects.